{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T17:36:05Z","timestamp":1747157765827,"version":"3.40.5"},"reference-count":33,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001868","name":"National Science Council, Taiwan","doi-asserted-by":"crossref","award":["NSC-102-2410-H-002-058-MY2"],"award-info":[{"award-number":["NSC-102-2410-H-002-058-MY2"]}],"id":[{"id":"10.13039\/501100001868","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.clinthera.2014.06.034","type":"journal-article","created":{"date-parts":[[2014,8,15]],"date-time":"2014-08-15T17:18:10Z","timestamp":1408123090000},"page":"1287-1294","source":"Crossref","is-referenced-by-count":4,"title":["Suboptimal Duration of Granulocyte Colony\u2013stimulating Factor Use and Chemotherapy-induced Neutropenia in Women Diagnosed With Breast Cancer"],"prefix":"10.1016","volume":"36","author":[{"given":"Wan-Ting","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Wen","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Ru","family":"Chien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Churn-Shiouh","family":"Gau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shao C.","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1660-9120","authenticated-orcid":false,"given":"Fei-Yuan","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2014.06.034_bib1","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cncr.11882","article-title":"Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management","volume":"100","author":"Crawford","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2014.06.034_bib2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/cid\/ciq147","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2014.06.034_bib3","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.21847","article-title":"Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients","volume":"106","author":"Kuderer","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2014.06.034_bib4","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00277-007-0399-y","article-title":"Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP","volume":"87","author":"Bosly","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clinthera.2014.06.034_bib5","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10549-008-0018-1","article-title":"Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients","volume":"114","author":"Chirivella","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clinthera.2014.06.034_bib6","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00520-011-1306-6","article-title":"Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma","volume":"20","author":"Pettengell","year":"2012","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2014.06.034_bib7","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/sj.bjc.6601279","article-title":"Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients","volume":"89","author":"Leonard","year":"2003","journal-title":"Br J Cancer"},{"journal-title":"National Comprehensive Cancer Network","article-title":"NCCN Clinical Practice Guideline in Oncology: Myeloid Growth Factors","year":"2012","key":"10.1016\/j.clinthera.2014.06.034_bib8"},{"key":"10.1016\/j.clinthera.2014.06.034_bib9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","article-title":"2010 Update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours","volume":"47","author":"Aapro","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clinthera.2014.06.034_bib10","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","article-title":"2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2014.06.034_bib11","doi-asserted-by":"crossref","first-page":"i80","DOI":"10.1093\/annonc\/mdi813","article-title":"ESMO recommendations for the application of hematopoietic growth factors","volume":"16","author":"Greil","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2014.06.034_bib12","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1182\/blood.V88.6.1907.bloodjournal8861907","article-title":"Filgrastim (r-metHuG-CSF): the first 10 years","volume":"88","author":"Welte","year":"1996","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2014.06.034_bib13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/00003495-200262001-00007","article-title":"Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia","volume":"62","author":"Crawford","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2014.06.034_bib14","doi-asserted-by":"crossref","first-page":"337","DOI":"10.18553\/jmcp.2007.13.4.337","article-title":"Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices","volume":"13","author":"Morrison","year":"2007","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.clinthera.2014.06.034_bib15","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1345\/aph.1G516","article-title":"Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?","volume":"40","author":"Weycker","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2014.06.034_bib16","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/annonc\/mdf130","article-title":"Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer","volume":"13","author":"Holmes","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2014.06.034_bib17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/annonc\/mdg019","article-title":"A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy","volume":"14","author":"Green","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2014.06.034_bib18","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3109\/10428190009089435","article-title":"A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin\u2019s lymphoma","volume":"37","author":"Intragumtornchai","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clinthera.2014.06.034_bib19","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/j.1365-2141.2008.07514.x","article-title":"Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study","volume":"144","author":"Pettengell","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clinthera.2014.06.034_bib20","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00520-010-0821-1","article-title":"Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer","volume":"19","author":"Hosmer","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2014.06.034_bib21","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2165\/11206870-000000000-00000","article-title":"Lenograstim: a review of its use in chemotherapy-induced neutropenia, for acceleration of neutrophil recovery following haematopoietic stem cell transplantation and in peripheral blood stem cell mobilization","volume":"71","author":"Keating","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2014.06.034_bib22","unstructured":"GRANOCYTE\u00ae (lenograstim) Prescribing Information. Amgen Manufacturing, Thousand Oaks, California, 2007. Chugai Pharmaceutical Co., Taipei, Taiwan, 2007. http:\/\/www.fda.gov.tw\/licnquery\/DO81E0T1.asp?LicId=10000757. Accessed September 5, 2014"},{"key":"10.1016\/j.clinthera.2014.06.034_bib23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.clinthera.2014.06.034_bib24","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00520-010-0840-y","article-title":"Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study","volume":"19","author":"Schwenkglenks","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2014.06.034_bib25","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1200\/JCO.1996.14.2.636","article-title":"Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia","volume":"14","author":"Blay","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2014.06.034_bib26","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/sj.bjc.6600724","article-title":"Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy","volume":"88","author":"Ray-Coquard","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clinthera.2014.06.034_bib27","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","article-title":"Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review","volume":"25","author":"Kuderer","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2014.06.034_bib28","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1200\/JCO.2008.16.2933","article-title":"Sweet syndrome associated with granulocyte colony-stimulating factor","volume":"26","author":"Bidyasar","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2014.06.034_bib29","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/BF03262329","article-title":"Economic evaluations of granulocyte colony-stimulating factor: in the prevention and treatment of chemotherapy-induced neutropenia","volume":"21","author":"Esser","year":"2003","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clinthera.2014.06.034_bib30","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s10147-010-0134-x","article-title":"Usage of granulocyte colony-stimulating factor every 2 days is clinically useful and cost-effective for febrile neutropenia during early courses of chemotherapy","volume":"16","author":"Yakushijin","year":"2011","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clinthera.2014.06.034_bib31","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jval.2010.10.037","article-title":"Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom","volume":"14","author":"Whyte","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2014.06.034_bib32","unstructured":"Drug reimbursement regulation, chapter 4, Blood derivatives. National Health Insurance Administration, Ministry of Health and Welfare, 2013. http:\/\/www.nhi.gov.tw\/webdata\/webdata.aspx?menu=21&menu_id=713&webdata_id=2919. Accessed September 5, 2014"},{"key":"10.1016\/j.clinthera.2014.06.034_bib33","first-page":"10","article-title":"Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients","author":"Renner","year":"2012","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814004299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814004299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T21:11:44Z","timestamp":1649970704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291814004299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0149291814004299"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2014.06.034","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2014,9]]}}}